

Publications

1. Heeregrave EJ, Geels MJ, Brenchley JM, Baan E, Ambrozak DR, **van der Sluis RM**, Bennemeer R, Douek DC, Goudsmit J, Pollakis G, Koup RA, Paxton WA. Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets. *Virology* **2009** 10;393(1):24-32
2. Heeregrave EJ, Geels MJ, Baan E, **van der Sluis RM**, Paxton WA, Pollakis G. Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte subpopulations upon ART initiation. *AIDS Res. Ther.* **2010** 6;7(1):42-49
3. Centlivre M, Legrand N, Steingrover R, **van der Sluis R**, Grijsen ML, Bakker M, Jurriaans S, Berkhout B, Paxton WA, Prins JM, Pollakis G. Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. *J. Leukoc. Biol.* **2011** 89(5):785-95
4. Orelia C, **van der Sluis RM**, Verkuijlen P, Nethe M, Hordijk PL, van den Berg TK, Kuijpers TW. Altered Intracellular Localization and Mobility of SBDS Protein upon Mutation in Shwachman-Diamond Syndrome. *PLoS ONE* **2011** 6(6):e20727
5. **van der Sluis RM**, Pollakis G, van Gerven ML, Berkhout B and Jeeninga RE. Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter. *Retrovirology* **2011** 8:73-85
6. **van der Sluis RM**, van Montfort T, Centlivre M, Schopman NCT, Cornelissen M, Sanders RW, Berkhout B, Jeeninga RE, Paxton WA and Pollakis G. Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity. *J. Virol. Methods* **2013** 187(1):94-102
7. Baan E, **van der Sluis RM**, Bakker M, Bekker V, Pajkrt D, Jurriaans S, Kuijpers TW, Berkhout B, Wolthers KC, Paxton WA and Pollakis G. Human immunodeficiency 1 virus type 1 gp120 envelope characteristics associated with disease progression differ in family members infected with genetically similar viruses. *J. Gen. Virol* **2013** 94:20-29
8. Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J, Cron R, **van der Sluis R**, Jeeninga R, Berkhout B and Kutsch O. An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. *Journal of Virology* **2013** 87(4):2264-77
9. **van der Sluis RM**, van Montfort T, Pollakis G, Sanders RW, Speijer D, Berkhout B and Jeeninga RE. Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. *PLoS Pathog* **2013** 9(3): e1003259
10. **van der Sluis RM**, Jeeninga RE and Berkhout B. Establishment and molecular mechanisms of HIV-1 latency in T cells. *Current Opinion in Virology* **2013** 3(6):700-6
11. **van der Sluis RM**, Derking R, Breidel S, Speijer D, Berkhout B, Jeeninga RE. Interplay between viral Tat protein and c-Jun transcription factor in controlling LTR promoter activity in different human immunodeficiency virus type I subtypes. *J. Gen. Virol* **2014** 95(4):968-79
12. **van der Sluis RM**, van Capel TMM, Sanders RW, de Jong EC, Berkhout B, Jeeninga RE and van Montfort T. Dendritic Cell Type-Specific HIV-1 Activation in Effector T-cells: Implications for Latent HIV-1 reservoir establishment. *AIDS* **2015** 29:1003-1014
13. To EE, Vlahos R, Luong R, Halls ML, Reading PC, King PT, Chan C, Drummond GR, Sobey CG, Broughton BRS, Starkey MR, **van der Sluis R**, Lewin SR, Bozinovski S, O'Neill LAJ, Quach T, Porter CJH, Brooks DA, O'Leary JJ and Selemidis S. Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. *Nature Communications* **2017** 12;8(1):69
14. Evans VA, **Van Der Sluis RM**, Solomon A, Dantanarayana A, McNeil C, Garsia R, Palmer S, Fromentin R, Chomont N, Sékaly RP, Cameron PU and Lewin SR. PD-1 contributes to the establishment and maintenance of HIV-1 latency. *AIDS*. **2018** 17;32(11):1491-1497
15. Kumar N, **van der Sluis RM**, Mota T, Pascoe R, Evans VA, Lewin SR and Cameron PU. Myeloid DC induce latency in proliferating CD4+ T-cells. *J. Immunology*. 2018 accepted for publication.